Zobrazeno 1 - 10
of 625
pro vyhledávání: '"Ben Jenkins"'
Publikováno v:
Utah Valley Magazine; Sep/Oct2023, Vol. 24 Issue 5, p18-18, 1/2p
Autor:
Robert Brown, Christina Yap, Johann De Bono, Malaka Ameratunga, Anna Minchom, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Ana Ferreira, Claudia Bertan, Rita Pereira, Chloe Baker, Nina Tunariu, Suzanne Carreira, Udai Banerji, Juanita Lopez, Alison Turner, Wentin Chen, Abhijit Pal, Dionysis Papadatos-Pastos, Toby Prout, Maxime Chénard-Poirier, Andra Curcean, Nahal Masrour, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Mona Parmar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/b9a84246b2264ed1b2c2acbbf2f19d79
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 03/04/2024.
Publikováno v:
Philosophical Psychology. :1-27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b4d18421afa83711ec8039a463a8733
https://doi.org/10.1080/09515089.2023.2213245
https://doi.org/10.1080/09515089.2023.2213245
Autor:
Nicholas Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley, Matthew Beaney, Lisa Fox, Katie Goddard, Isaac Garcia-Murillas, Peter Hall, Catherine Harper-Wynne, Tamas Hickish, Sarah Kernaghan, Iain Macpherson, Alicia Okines, Carlo Palmieri, Sophie Perry, Katrina Randle, Claire Snowdon, Hilary Stobart, Andrew Wardley, Duncan Wheatley, Simon Waters, Matthew Winter, Judith Bliss
Publikováno v:
Cancer Research. 82:GS3-06
Background Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage triple negative breast cancer (TNBC) is associated with a very high risk of future relapse. Identifiying those at high risk of subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c87025dfbe68a40c7a5f74097df5e6c8
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
Autor:
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud, Ruth Riisnaes, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout, Mona Parmar, Anna Zachariou, Alison Turner, Ben Jenkins, Stuart McIntosh, Ed Ainscow, Anna Minchom, Juanita Lopez, Johann de Bono, Robert Jones, Emma Hall, Natalie Cook, Bristi Basu, Udai Banerji
Publikováno v:
Clinical Cancer Research. 28:4634-4641
Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors. Patients and Methods: A 3+3 dose escalation design was used. During do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5acc878b283c3c6e9cd5e46255c97453
https://doi.org/10.1158/1078-0432.ccr-22-1268
https://doi.org/10.1158/1078-0432.ccr-22-1268
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2704c4994794b5ac32f8afd095444629
https://doi.org/10.1158/1078-0432.22489008
https://doi.org/10.1158/1078-0432.22489008
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0475121ba5d79aa5db6a42030c640f34
https://doi.org/10.1158/1078-0432.22488999
https://doi.org/10.1158/1078-0432.22488999
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Purpose:CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors.Patients and Methods:A 3+3 dose escalation design was used. During dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2962569a9f2efd37fe6e40c644a7cac
https://doi.org/10.1158/1078-0432.c.6532860
https://doi.org/10.1158/1078-0432.c.6532860